Astral demerger plan: why shares fell 7% in 2026

Stock slides as restructuring details sink in

Astral Ltd shares fell sharply on Monday after the company announced a major restructuring of its existing business. The stock opened 4.7% lower at ₹1,417 on the NSE and fell to an intraday low reported between ₹1,385 and ₹1,371 in morning deals. Around 9:50 AM, Astral was down 6.2% at ₹1,394, while the Nifty 50 was modestly higher, up about 0.15% in one snapshot and 0.07% in another.

The sell-off came as investors assessed a composite corporate action that includes both a demerger and an amalgamation. The immediate price reaction suggests the market is factoring in near-term uncertainty around how each business will be valued once separated.

What the board approved: demerger plus amalgamation

Astral said its board approved a Composite Scheme of Arrangement. The scheme provides for the “demerger and transfer of the chemicals business undertaking along-with all its related assets and liabilities” of Astral Ltd into Astral Chemie Ltd (formerly Astral Coatings Pvt Ltd) on a going concern basis.

Separately, Astral will merge Al-Aziz Plastics Private Limited into Astral Ltd. Alongside the demerger, Astral Chemie is expected to be listed independently on both the NSE and BSE, subject to approvals.

Business split: what stays with Astral and what moves out

Post demerger, Astral said its plumbing-related businesses will remain with Astral Ltd. These include pipes and fittings, bathware, and CPVC resin.

The demerged chemicals undertaking includes adhesives, paints, and speciality chemicals, as referenced in market reports around the announcement. The intent, as described by broker notes cited in the coverage, is to create two more focused entities with independent capital allocation and dedicated management attention.

Share entitlement and expected timeline

Under the scheme’s share entitlement terms mentioned in the coverage, shareholders are expected to receive one equity share of Astral Chemie (face value Re 1 each) for every one equity share held in Astral Ltd (face value Re 1 each). The record date is to be announced.

The demerger process is expected to take around 9 to 12 months to complete, as per the referenced brokerage commentary. Until the transaction is completed and the resulting entity lists, investors typically track timelines, regulatory approvals, and the final scheme documents that define the separation mechanics.

Key numbers investors tracked on the day

Astral’s decline was notable because it contrasted with a flat-to-positive broader market. Reports also cited that the stock has fallen 7.15% over the last 12 months and is up 0.41% year-to-date.

Price action snapshot

Chemicals business scale: FY26 revenue and medium-term target

One data point highlighted in the coverage is that Astral’s chemicals business contributed ₹1,266.3 crore in FY26, accounting for 21% of Astral’s total turnover.

A separate brokerage note cited management’s medium-term objective for Astral Chemie: expanding revenue from ₹1,860 crore in FY26 to about ₹4,400 to ₹5,000 crore over the next four to five years, while improving EBITDA margins to 14% to 15%. These figures were presented as targets, not as reported results.

What brokerages said: near-term overhang vs value-unlocking

Different brokerages framed the demerger’s impact in different ways, even while maintaining constructive views on the stock.

Equirus Securities said the demerger could create a near-term overhang as investors work out what valuation multiples each business might command post listing. Equirus kept a ‘Long’ rating with a target price of ₹1,980, implying an upside of 33% from the previous close of ₹1,487.

Antique maintained a ‘Buy’ rating with a target price of ₹1,630, citing a P/E multiple of 50x FY28 EPS (with a five-year high/average/low multiple range of 119x/79x/49x mentioned in the note).

Investec maintained a ‘Buy’ with a target price of ₹1,710 and described the restructuring as a potential value-unlocking trigger under the theme of “1+1 > 2”, pointing to sharper focus and improved capital allocation.

JM Financial maintained an ‘ADD’ rating with a target of ₹1,600, and said key monitorables for Astral Chemie post-demerger include funding growth initiatives, improving profitability, and navigating competitive pressures.

ICICI Securities also reiterated a positive stance, noting the demerger could lead to greater disclosures from both businesses and enable investors to value each business better. Its revised SoTP-based Mar’27E target price was cited at ₹1,738, while another broker note referenced a revised SoTP-based target price of ₹1,779.

Broker targets cited in the coverage

Market impact: why the stock fell despite supportive ratings

The key market factor cited was uncertainty, not a change in the underlying corporate intent. A demerger can complicate near-term valuation because the market must decide separate multiples for two businesses that previously traded as one.

The intraday decline also came as investors weighed the execution path: a 9 to 12 month process, multiple approvals, and eventual listing of Astral Chemie. In such events, price discovery can remain uneven until investors see clearer segment-level financials and understand how each entity will fund growth independently.

Why the restructuring matters for investors

At a basic level, the restructuring is designed to separate plumbing operations from chemicals (including adhesives and paints) under two listed vehicles. Broker commentary indicated that one expected outcome is more granular disclosure, which can reduce a “conglomerate discount” and allow each business to be valued on its own performance profile.

At the same time, the coverage flagged that investors are assessing growth prospects for the remaining segments and the competitive dynamics in chemicals-linked categories. That debate, along with the eventual listing and financial reporting structure, is likely to drive investor attention until the scheme is completed.

Conclusion

Astral’s sharp move reflects the market’s first-pass reaction to a major corporate action: demerging the chemicals business into Astral Chemie, listing it separately, and merging Al-Aziz Plastics into Astral. While several brokerages retained positive ratings and targets, they also highlighted near-term uncertainty around valuations and execution. The next key milestones, based on the information cited, are the approval process and the expected 9 to 12 month timeline leading up to the demerger’s completion and Astral Chemie’s separate listing.